Literature DB >> 18801705

A comparison of IFNgamma detection methods used in tuberculosis vaccine trials.

Natalie E R Beveridge1, Helen A Fletcher, Jane Hughes, Ansar A Pathan, Thomas J Scriba, Angela Minassian, Clare R Sander, Kathryn T Whelan, Hazel M Dockrell, Adrian V S Hill, Willem A Hanekom, Helen McShane.   

Abstract

Interferon gamma (IFNgamma) is a critical component of the pro-inflammatory immune response that provides protection against Mycobacterium tuberculosis. In the absence of an immunological correlate of protection, antigen-specific production of IFNgamma is a commonly used marker of a protective immune response. To facilitate the evaluation of tuberculosis candidate vaccines three different IFNgamma detection methods were compared. The cultured whole blood ELISA, ex vivo IFNgamma ELISpot and whole blood ex vivo intracellular cytokine staining (ICS) assays were performed head-to-head during a Phase I clinical trial using the candidate vaccine MVA85A. Whilst all three assays detected significant increases in IFNgamma production immediately following vaccination, distinctions between the assays were apparent. Higher baseline IFNgamma responses were detected using the cultured whole blood ELISA, whereas the ex vivo ELISpot assay was the most sensitive in detecting long-term (52 weeks) post-vaccination responses. The whole blood ex vivo ICS assay provided novel information by dissecting the IFNgamma response into responding CD4, CD8 and gamma/delta T cell subsets. Future tuberculosis vaccine trials and immunology studies should ideally include a combination of ex vivo and cultured assays to ensure a thorough and multifaceted evaluation of the immune response is achieved.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18801705     DOI: 10.1016/j.tube.2008.06.005

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  26 in total

1.  Immunogenicity of a protective whole cell mycobacterial vaccine in HIV-infected adults: a phase III study in Tanzania.

Authors:  Timothy Lahey; Robert D Arbeit; Muhammad Bakari; C Robert Horsburgh; Mecky Matee; Richard Waddell; Lillian Mtei; Jenni M Vuola; Kisali Pallangyo; C Fordham von Reyn
Journal:  Vaccine       Date:  2010-09-25       Impact factor: 3.641

Review 2.  Tuberculosis vaccines in clinical trials.

Authors:  Rosalind Rowland; Helen McShane
Journal:  Expert Rev Vaccines       Date:  2011-05       Impact factor: 5.217

3.  Investigating the induction of vaccine-induced Th17 and regulatory T cells in healthy, Mycobacterium bovis BCG-immunized adults vaccinated with a new tuberculosis vaccine, MVA85A.

Authors:  Simone C de Cassan; Ansar A Pathan; Clare R Sander; Angela Minassian; Rosalind Rowland; Adrian V S Hill; Helen McShane; Helen A Fletcher
Journal:  Clin Vaccine Immunol       Date:  2010-05-19

4.  Mycobacterium bovis BCG Vaccination Induces Divergent Proinflammatory or Regulatory T Cell Responses in Adults.

Authors:  Mardi C Boer; Corine Prins; Krista E van Meijgaarden; Jaap T van Dissel; Tom H M Ottenhoff; Simone A Joosten
Journal:  Clin Vaccine Immunol       Date:  2015-05-06

5.  Enhancing sensitivity of detection of immune responses to Mycobacterium leprae peptides in whole-blood assays.

Authors:  Annemieke Geluk; Jolien J van der Ploeg-van Schip; Krista E van Meijgaarden; Susanna Commandeur; Jan W Drijfhout; Willemien E Benckhuijsen; Kees L M C Franken; Bernard Naafs; Tom H M Ottenhoff
Journal:  Clin Vaccine Immunol       Date:  2010-04-28

6.  In vitro analysis of antigen induced T cell-monocyte conjugates by imaging flow cytometry.

Authors:  Meseret Habtamu; Markos Abebe; Abraham Aseffa; Anne Margarita Dyrhol-Riise; Anne Spurkland; Greger Abrahamsen
Journal:  J Immunol Methods       Date:  2018-07-04       Impact factor: 2.303

7.  Plasmodium falciparum apical membrane antigen 1 vaccine elicits multifunctional CD4 cytokine-producing and memory T cells.

Authors:  Maria Cecilia Huaman; Gregory E D Mullen; Carole A Long; Siddhartha Mahanty
Journal:  Vaccine       Date:  2009-07-08       Impact factor: 3.641

8.  Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells.

Authors:  Thomas J Scriba; Michele Tameris; Nazma Mansoor; Erica Smit; Linda van der Merwe; Fatima Isaacs; Alana Keyser; Sizulu Moyo; Nathaniel Brittain; Alison Lawrie; Sebastian Gelderbloem; Ashley Veldsman; Mark Hatherill; Anthony Hawkridge; Adrian V S Hill; Gregory D Hussey; Hassan Mahomed; Helen McShane; Willem A Hanekom
Journal:  Eur J Immunol       Date:  2010-01       Impact factor: 5.532

9.  Evaluation of the safety and immunogenicity of a candidate tuberculosis vaccine, MVA85A, delivered by aerosol to the lungs of macaques.

Authors:  A D White; L Sibley; M J Dennis; K Gooch; G Betts; N Edwards; A Reyes-Sandoval; M W Carroll; A Williams; P D Marsh; H McShane; S A Sharpe
Journal:  Clin Vaccine Immunol       Date:  2013-02-27

10.  Reduced frequency of memory T cells and increased Th17 responses in patients with active tuberculosis.

Authors:  Nancy D Marín; Sara C París; Mauricio Rojas; Luis F García
Journal:  Clin Vaccine Immunol       Date:  2012-08-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.